Clinical Trial Update: Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

View source ↗

Summary

A completed clinical trial sponsored by Stanford University comparing bimonthly VEGF Trap-Eye (aflibercept) dosing to as-needed administration or other therapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• VEGF Trap-Eye (aflibercept)

Snippet

Sponsor: Stanford University | Conditions: Exudative Age-related Macular Degeneration | Status: COMPLETED